Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer.
It operates through Oncology Innovation Platform and Commercial Platform segments.
The company's Orascovery product candidates include Oral paclitaxel and encequidar for the treatment of metastatic breast cancer.
It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis.
In addition, the company engages in developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinoma.
Further, it engages in developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors.
The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015.
Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.
On May 14, 2023, Athenex, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in theU. S.
Bankruptcy Court for the Southern District of Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 31, 23 | 0.00 Increased by +100.00% | -1.71 Increased by +100.00% |
| Mar 20, 23 | -4.28 Increased by +33.13% | -1.73 Decreased by -147.40% |
| Nov 3, 22 | -2.80 Increased by +57.58% | -3.00 Increased by +6.67% |
| Jul 28, 22 | -5.60 Increased by +15.15% | -3.00 Decreased by -86.67% |
| May 10, 22 | -3.20 Increased by +40.74% | -3.80 Increased by +15.79% |
| Mar 16, 22 | -6.40 Increased by +39.62% | -3.53 Decreased by -81.30% |
| Nov 4, 21 | -6.60 Increased by +25.00% | -7.37 Increased by +10.45% |
| Aug 5, 21 | -6.60 Increased by +34.00% | -7.33 Increased by +9.96% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 22 | 25.06 M Increased by +0.51% | -28.77 M Increased by +70.45% | Decreased by -114.78% Increased by +70.60% |
| Sep 30, 22 | 33.53 M Increased by +3.82% | -19.62 M Increased by +45.60% | Decreased by -58.50% Increased by +47.60% |
| Jun 30, 22 | 31.52 M Increased by +43.76% | -24.03 M Increased by +29.88% | Decreased by -76.26% Increased by +51.22% |
| Mar 31, 22 | 29.72 M Decreased by -27.55% | -30.47 M Decreased by -21.63% | Decreased by -102.51% Decreased by -67.88% |
| Dec 31, 21 | 24.94 M Increased by +14.34% | -97.35 M Decreased by -96.70% | Decreased by -390.40% Decreased by -72.02% |
| Sep 30, 21 | 32.30 M Decreased by -8.96% | -36.06 M Increased by +2.03% | Decreased by -111.64% Decreased by -7.61% |
| Jun 30, 21 | 21.92 M Decreased by -45.43% | -34.27 M Increased by +15.27% | Decreased by -156.34% Decreased by -55.26% |
| Mar 31, 21 | 41.02 M Decreased by -12.59% | -25.05 M Decreased by -28.93% | Decreased by -61.06% Decreased by -47.50% |